Patents by Inventor Junji Onoda

Junji Onoda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210221876
    Abstract: Objective of the present invention is to provide a novel monoclonal antibody against Nav1.7. The present invention discloses a monoclonal antibody against Nav1.7 or its antibody fragment, having specific six CDRs (CDR1 to CDR3 of a heavy chain and CDR1 to CDR3 of a light chain) or specific heavy/light chain variable regions. The monoclonal antibody and the like can be used for treating or preventing pain, pruritus and so on.
    Type: Application
    Filed: May 30, 2019
    Publication date: July 22, 2021
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Tatsuya TAKAHASHI, Mai YOSHIKAWA, Sosuke YONEDA, Junji ONODA, Etsuo NAKAMURA, Tsuguo MIYAUCHI, Toshiyuki ASAKI, Erika KASAI
  • Patent number: 10745491
    Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 18, 2020
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
  • Publication number: 20190211114
    Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Application
    Filed: January 11, 2019
    Publication date: July 11, 2019
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Shoichi NAITO, Junji ONODA, Tasuku TSUKAMOTO, Katsutoshi YAMADA, Shoji YAMANE, Yoshito NUMATA, Kazuhiko MAEKAWA, Tatsuya TAKAHASHI
  • Patent number: 10239955
    Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: March 26, 2019
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
  • Publication number: 20170275378
    Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Application
    Filed: June 2, 2017
    Publication date: September 28, 2017
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Shoichi NAITO, Junji ONODA, Tasuku TSUKAMOTO, Katsutoshi YAMADA, Shoji YAMANE, Yoshito NUMATA, Kazuhiko MAEKAWA, Tatsuya TAKAHASHI
  • Patent number: 9701757
    Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: July 11, 2017
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
  • Patent number: 9296825
    Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits enzyme activity of EL and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: March 29, 2016
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi, Yasuhiko Sato
  • Publication number: 20160009819
    Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 14, 2016
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Shoichi NAITO, Junji ONODA, Tasuku TSUKAMOTO, Katsutoshi YAMADA, Shoji YAMANE, Yoshito NUMATA, Kazuhiko MAEKAWA, Tatsuya TAKAHASHI
  • Patent number: 9222947
    Abstract: Provided are a monoclonal antibody capable of specifically recognizing a specific region of sAPP ? or a fragment of said antibody and an assay method and an assay kit using the same, in order to accurately assay sAPP? contained in a biological sample.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: December 29, 2015
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Tatsuya Takahashi, Junji Onoda, Yasunobu Yoshida, Shoji Yamane, Kouhei Nishitomi, Hidekuni Yamakawa, Akira Yamauchi, Atsushi Morita, Isao Fukuda
  • Publication number: 20150111231
    Abstract: Provided are a monoclonal antibody capable of specifically recognizing a specific region of sAPP ? or a fragment of said antibody and an assay method and an assay kit using the same, in order to accurately assay sAPP? contained in a biological sample.
    Type: Application
    Filed: February 1, 2013
    Publication date: April 23, 2015
    Inventors: Tatsuya Takahashi, Junji Onoda, Yasunobu Yoshida, Shoji Yamane, Kouhei Nishitomi, Hidekuni Yamakawa, Akira Yamauchi, Atsushi Morita, Isao Fukuda
  • Publication number: 20150025225
    Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits enzyme activity of EL and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Application
    Filed: October 11, 2012
    Publication date: January 22, 2015
    Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi, Yasuhiko Sato
  • Patent number: 8722856
    Abstract: An object of the present invention is to provide an antibody which does not bind to a normal cell, and is specific for a cancer cell. The object was solved by the finding by the present inventors that an antibody obtained by immunizing an animal using a 2,3ST glycopeptide as an antigen unexpectedly recognizes a sugar chain specific for a cancer specifically and remarkably, and consequently, can recognize and kill a cancer cell expressing MUC1 having such a cancer cell-specific sugar chain. The present invention provides, for example, an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, in which specificity for a cancer-associated structure of MUC1 is 100-fold or more as compared with that for a normal tissue-associated structure of MUC1.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: May 13, 2014
    Assignees: National University Corporation Hokkaido University, Shionogi & Co., Ltd.
    Inventors: Shin-Ichiro Nishimura, Hiroshi Hinou, Yoshito Numata, Junji Onoda, Shoichi Naito, Naoki Ohyabu
  • Patent number: 8536313
    Abstract: A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: September 17, 2013
    Assignee: Shionogi & Co., Ltd.
    Inventors: Shoichi Naito, Junji Onoda, Akira Yamauchi, Yoshito Numata, Junji Kishono
  • Publication number: 20120237948
    Abstract: The present invention provides a novel monoclonal antibody that is specific for a C-terminal neoepitope of a collagen fragment and has substantially equal binding affinity whether proline contained in the neoepitope is in a non-hydroxylated form or in a hydroxylated form, and an immunoassay, a measurement method, a kit and the like using the antibody. The antibody allows for quantification of a collagen fragment generated by digestion of a biological sample with a collagenase present in the sample, regardless of the presence or absence of a hydroxylated form of proline in the neoepitope.
    Type: Application
    Filed: September 16, 2010
    Publication date: September 20, 2012
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yoshito Numata, Akira Yamauchi, Junji Onoda, Shoji Yamane, Tomoko Maeda
  • Publication number: 20120040375
    Abstract: An object of the present invention is to provide an antibody which does not bind to a normal cell, and is specific for a cancer cell. The object was solved by the finding by the present inventors that an antibody obtained by immunizing an animal using a 2,3ST glycopeptide as an antigen unexpectedly recognizes a sugar chain specific for a cancer specifically and remarkably, and consequently, can recognize and kill a cancer cell expressing MUC1 having such a cancer cell-specific sugar chain. The present invention provides, for example, an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, in which specificity for a cancer-associated structure of MUC1 is 100-fold or more as compared with that for a normal tissue-associated structure of MUC1.
    Type: Application
    Filed: October 28, 2009
    Publication date: February 16, 2012
    Applicants: SHIONOGI & CO., LTD.
    Inventors: Shin-Ichiro Nishimura, Hiroshi Hinou, Yoshito Numata, Junji Onoda, Shoichi Naito, Naoki Ohyabu
  • Publication number: 20100330092
    Abstract: A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.
    Type: Application
    Filed: July 8, 2008
    Publication date: December 30, 2010
    Applicant: SHIONLGI & CO., LTD.
    Inventors: Shoichi Naito, Junji Onoda, Akira Yamauchi, Yoshito Numata, Junji Kishono
  • Publication number: 20090298196
    Abstract: The present invention is intended to provide a method of rapidly, simply and accurately measuring a recombinant protein. As means for resolution, the protein quantity is measured by causing the expression of a fusion protein with the target protein and epitope tags containing two types of epitopes, bringing them into contact with detection antibodies which specifically recognize each epitope, and detecting a phenomenon caused by both detection antibodies coming close to each other.
    Type: Application
    Filed: January 26, 2006
    Publication date: December 3, 2009
    Inventors: Ken-ichiro Uwabe, Koji Enomoto, Junji Onoda, Yoshito Numata, Hiroshi Takemoto